Receptors: Perspectives in Pathology and Clinical Medicine

References

• Langley J. N. On nerve-endings and on special excitable substances in cells. (Croonian Lecture, Royal Society.). Proc. Roy. Soc., B. 1906; vol. LXXVIII: 170–194
   Google Scholar
• Ehrlich P. Address in pathology: on chemiotherapy. Brit. med. J. 1913; II: 353
   Google Scholar
• Ariëns E. J., Simonis A. M. Cholinergic and anticholinergic drugs, do they act on common receptors?. Ann. NY Acad. Sci. 1967; 144: 842–868
   PubMed Web of Science ®Google Scholar
• Ariëns E. J. Receptors: from fiction to fact. TIPS 1979; 1: 11–15
   Web of Science ®Google Scholar
• Ariëns E. J., Beld A. J., Rodrigues de Miranda J. F., Simonis A. M. The pharmacon-receptor-effector concept, in The receptors. General principles and procedures, R. D. O'Brien. Plenum Press, New York 1979; vol. I: 33–91
   Google Scholar
• Ariëns E. J., Simonis A. M. Physiological and pharmacological aspects of adrenergic receptor classification. Biochem. Pharmacol. 1983; 32: 1539–1545
   PubMed Web of Science ®Google Scholar
• Paterson S. J., Robson L. E., Kosterlitz H. W. Classification of opioid receptors. Br. Med. Bull. 1983; 39: 31–36
   PubMed Web of Science ®Google Scholar
• Costall B., Naylor R. J. The hypotheses of different dopamine receptor mechanisms. Life Sci. 1981; 28: 215–229
   PubMed Web of Science ®Google Scholar
• Laduron P. M. Criteria for receptor sites in binding studies. Biochem. Pharmacol. 1984; 33: 833–839
   PubMed Web of Science ®Google Scholar
• Martin W. R. A new receptor nomenclature. Life Sci. 1981; 28: 1555–1557
   PubMed Web of Science ®Google Scholar
• Seeman Ph. Nomenclature of central and peripheral dopaminergic sites and receptors. Biochem. Pharmacol. 1982; 31: 2563–2568
   PubMed Web of Science ®Google Scholar
• Int. Union of Biochemistry. Enzyme nomenclature. Recommandations 1978 of the Nomenclature Committee. Academic Press, New York 1979; 6–11
   Google Scholar
• Olsen R. W., Reisine T. D., Yamamura H. I. Neurotransmitter receptors - biochemistry and alterations in neuropsychiatric disorders. Life Sci. 1980; 27: 801–808
   PubMed Web of Science ®Google Scholar
• Rubenstein E. Diseases caused by impaired communication among cells. Sci. Am. 1980; 242/3: 78–87
   Web of Science ®Google Scholar
• Block L. H., Tenschert W., Locher R., Siegenthaler W., Vetter W. Receptor dysfunctions in human disease. Klin. Wochenschr. 1981; 59: 355–363
   PubMedGoogle Scholar
• Roth J., Taylor S. I. Receptors for peptide hormones: alterations in diseases of humans. Ann. Rev. Physiol. 1982; 44: 639–651
   PubMed Web of Science ®Google Scholar
• Kelly J., O'Malley K. Adrenoceptor function and ageing. Clin. Sci. 1984; 66: 509–515
   Web of Science ®Google Scholar
• Werner S. C., Von Westarp Ch. The thyroid and immunology. Life Sci. 32/1 and 1983; 2: 1–163
   Web of Science ®Google Scholar
• Galjaard H. Van mensen naar moleculen… en terug?. Ned. T. Geneesk. 1982; 126: 2335–2343
   PubMedGoogle Scholar
• Given B. D., Mako M. E., Tager H. S., Baldwin D., Markese J., Rubenstein A. H., Olefsky J., Kobayashi M., Kolterman O., Poucher R. Diabetes due to secretion of an abnormal insulin. N. Engl. J. Med. 1980; 302: 129–135
   PubMed Web of Science ®Google Scholar
• Veldhuis J. D., Kulin H. E., Santen R. J., Wilson Th. E., Melby J. C. Inborn error in the terminal step of aldosterone biosynthesis. N. Engl. J. Med. 1980; 303: 117–121
   PubMed Web of Science ®Google Scholar
• Griffin J. E., Wilson J. D. The syndromes of androgen resistance. N. Engl. J. Med. 1980; 302: 198–209
   PubMed Web of Science ®Google Scholar
• Tenschert W., Vetter H., Siegenthaler W., Vetter W. Rezeptordysfunktion als pathogenetisches Prinzip bei Hormonresistenz und Stoffwechselerkrankungen. Schweiz. med. Wschr. 1981; 111: 174–181
   PubMedGoogle Scholar
• Bowman W. C., Rand M. J. Textbook of Pharmacology. Second Edition. Blackwell Scientific Publications, Oxford 1980; 30
   Google Scholar
• Evered D., Whelan J. Receptors, antibodies and disease. Ciba Foundation symposium. Pitman, London 1982; 90: 22–105
   Google Scholar
• Drachman D. B., Adams R. N., Josifek L. F., Self S. G. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 1982; 307: 769–775
   PubMed Web of Science ®Google Scholar
• Drachman D. B. Myasthenia gravis: immunobiology of a receptor disorder. TINS 1983; 6: 446–451
   Web of Science ®Google Scholar
• Lewin R. Myasthenia gravis under monoclonal scrutiny. Science 1981; 211: 38–42
   PubMed Web of Science ®Google Scholar
• Hearn M. T.W. Graves' disease and the thyrotrophin receptor. TIBS 1980; 5: 75–79
   Web of Science ®Google Scholar
• Strakosch Ch. R., Wenzel B. E., Row V. V., Volpé R. Immunology of autoimmune thyroid diseases. N. Engl. J. Med. 1982; 307: 1499–1505
   PubMed Web of Science ®Google Scholar
• Valente W. A., Vitti P., Rotella C. M., Vaughan M. M., Aloj S. M., Grollman E. F., Ambesi-Impiombato F. S., Kohn L. D. Antibodies that promote thyroid growth. N. Engl. J. Med. 1983; 309: 1028–1034
   PubMed Web of Science ®Google Scholar
• Taylor S. I., Grunberger G., Marcus-Samuels B., Underhill L. H., Dons R. F., Ryan J, Roddam R. F., Rupe C. E., Gorden Ph. Hypoglycemia associated with antibodies to the insulin receptor. N. Engl. J. Med. 1982; 307: 1422–1425
   PubMed Web of Science ®Google Scholar
• Arky R. A. Antibodies and disorders of glucose metabolism. N. Engl. J. Med. 1982; 307: 1445–1447
   PubMed Web of Science ®Google Scholar
• Motulsky H. J., Insel P. A. Adrenergic receptors in man. N. Engl. J. Med. 1982; 307: 18–29
   PubMed Web of Science ®Google Scholar
• Paterson J. W., Lulich K. M., Goldie R. G. The role of β-adrenoceptors in bronchial hyperreactivity. Bronchial hyperreactivity, J. Morley. Academic Press, New York 1982; 19
   Google Scholar
• Knight J. G. Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia. Lancet 1982; II: 1073–1075
   Google Scholar
• Gustafsson J. Å., Pousette Å., Wrange Ö. Predictive tests in treatment of breast and prostatic carcinoma based on steroid receptor assays. TIPS 1980; 1: 279–281
   Web of Science ®Google Scholar
• Manni A. Hormone receptors and breast cancer. N. Engl. J. Med. 1983; 309: 1383–1385
   PubMed Web of Science ®Google Scholar
• Clark G. M., Mc Guire W. L., Hubay Ch. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 1983; 309: 1343–1347
   PubMed Web of Science ®Google Scholar
• Skoog L., Nordenskjöld B., Öst Å., Andersson B., Hast R., Giannoulis N., Humla S., Hägerström T., Reizenstein P. Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute nonlymphocytic leukaemia. Br. med. J. 1981; 282: 1826–1829
   PubMedGoogle Scholar
• Schwartz M. K. Relevance of steroid receptor measurements in the diagnosis and therapeutic management of cancer patients, in Prostate cancer and hormone receptors. Prog. Clin. Biol. Res., G. P. Murphy, A. A. Sandberg. Alan R. Liss, New York 1979; 33: 201–208
   Google Scholar
• Ekman P. Clinical significance of steroid receptor assay in the human prostate, in Steroid receptors. metabolism and prostatic cancer, F. H. Schröder, H. J. de Voogt. Excerpta Medica, Amsterdam 1980; 208
   Google Scholar
• Overstreet D. H., Yamamura H. I. Receptor alterations and drug tolerance. Life Sci. 1979; 25: 1865–1878
   PubMed Web of Science ®Google Scholar
• Cummings D. M., Vlasses P. H. Antihypertensive drug withdrawal syndrome. Drug Intell. Clin. Pharm. 1982; 16: 817–822
   PubMed Web of Science ®Google Scholar
• Wamsley J. K., Gehlert D. R., Roeske W. R., Yamamura H. I. Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with (3H)-QNB and (3H)-pirenzepine. Life Sci. 1984; 34: 1395–1402
   PubMed Web of Science ®Google Scholar
• Palacios J. M., et al. J. Recept. Res. 1984, this issue
   Google Scholar
• Amenta F., Cavallotti C., De Rossi M., Vatrella F. Beta-adrenoceptors in the rat kidney. Naunyn Schmiedeberg's Arch. Pharmacol. 1983; 324: 94–98
   Google Scholar
• Baulieu E.-E. Pharmacology of steroid receptors: from molecular and cellular studies to efficient antihormonal drugs. Biochem. Pharmacol. 1984; 33: 905–912
   PubMed Web of Science ®Google Scholar
• Marchalonis J. J., Warr G. W. Antibody as a tool. John Wiley & Sons, Chichester 1982; 139, 447
   Google Scholar
• Barnard E. A. Visualization and counting of receptors at the light and electron microscope levels. General principles and procedures, R. D. O'Brien. Plenum Press, New York 1979; vol. I: 247
   Google Scholar
• Gregoriadis G. Targeting of drugs: implications in medicine. Lancet 1981; II: 241–246
   Google Scholar
• Goldberg E. P. Targeted drugs. John Wiley & Sons, New York 1982; 1
   Google Scholar
• Ariëns E. J. Drug design in cancer chemotherapy, in Medicinal Chemistry VI. Proc. 6th Int. Symp. Med. Chem. 1979, A. Simkin. Cotswold Press, Oxford, 289
   Google Scholar
• Metcalfe R. F. A sensitive radioreceptor assay for atropine in plasma. Biochem. Pharmacol. 1981; 30: 209–212
   PubMed Web of Science ®Google Scholar
• Ensinger H. A., Doevendans J. E. Plasma levels of opioid analgesics determined by radioreceptor assay. Arzneim.-Forsch./Drug Res. 1984; 34((I))609–610
   PubMedGoogle Scholar